Norfloxacin prophylaxis for acute recurrent uncomplicated urinary tract infection in women

Long-term low dose antimicrobial prophylaxis is effective for the prevention of recurrent uncomplicated urinary infections in women. The fluoroquinolone antimicrobials, including norfloxacin, have an in vitro spectrum effective for most uropathogens, and generally achieve high concentrations in the urine. In addition, they are effective for eradication of aerobic Gram-negative flora from the gut. These features suggest these antimicrobials should be effective agents for antimicrobial prophylaxis for urinary infection. Only norfloxacin has been studied in clinical trials to date. In two of the three studies reported, norfloxacin was effective for prophylaxis compared to placebo. In the third study, it was as effective as nitrofurantoin macrocrystals. Infections which occurred during prophylaxis were with organisms resistant to norfloxacin, particularly Enterococcus faecalis and Pseudomonas aeruginosa. Norfloxacin is effective for the prevention of recurrent uncomplicated urinary infections in women. Further studies comparing it to standard regimens are required to identify its specific niche in the management of this common problem.     

两种抗生素用药方案预防绝经后女性复发性尿路感染的比较

目的 比较两种抗生素用药方案对绝经后女性复发性尿路感染急性发作的预防效果。方法 采用前瞻性随机对照研究，将2004年8月至2007年9月本科门诊随访的68例绝经后女性复发性尿感患者随机分为两组，分别采用单剂量抗生素持续抑菌和患者自主的单剂量抗生素间歇抑菌两种预防方法。观察两组患者开始抗生素预防后的12个月内，尿路感染急性发作以及胃肠道症状、阴道真菌感染等不良反应的发生率。 结果 患者自主的间歇抑菌组与持续抑菌组的总有效率差异无统计学意义（71.0%比81.8%，P > 0.05），但前者胃肠道并发症发生率显著低于持续抑菌组（7.7%比28.6%，P < 0.05）。 结论 患者自主的单剂量抗生素间歇抑菌对绝经后女性尿路感染的反复发作有良好的预防效果，且较少引起胃肠道不良反应。     

Nitrofurantoin versus Trimethoprim for low-dose long-term prophylaxis in patients with recurrent urinary tract infections

In a prospective randomized study 38 patients with recurrent urinary tract infections (rUTI) were included to take either 50 mg Nitrofurantoin (n=19) or 50 mg Trimethoprim (n=19) as low-dose long-term prophylaxis for half a year. Compliance was checked weekly byBacillus subtilis spore test strips sent in by mail. The infection rate was reduced from more than three per patient year to 0.01. There were no significant differences between the two groups concerning the recurrence rate (Nitrofurantoin: one rUTI; Trimethoprim: three rUTI) or side effects. Under Nitrofurantoin treatment 3 symptomatic fungal infections occurred. Trimethoprim and Nitrofurantoin are equally suitable for low-dose long-term prophylaxis in rUTI. Surveillance of compliance gives important hints for failure of prophylaxis.     

Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women

The problem with recurrent urinary tract infections in women is enormous and contributes significantly to national health care costs. As the role of office urology and the external "cost-effective" pressures placed on the practicing urologist have heightened, a consistent, logical approach towards diagnosis and management of urinary tract infection becomes essential. This article briefly discusses the cause and pathophysiology behind recurrent urinary tract infections in women. A practical discussion of proper evaluation and treatment options will also be provided in hopes of offering the clinician a simple, stepwise approach to this sometimes difficult condition.     

Prevention and alternative methods for prophylaxis of recurrent urinary tract infections in women

General recommendations to prevent recurrent urinary tract infections (rUTI) result in about one-third of patients remaining free of recurrences. Oral and parenteral immunotherapy were effective in several controlled studies for prevention of rUTI. These therapies can be combined with acute antibiotic therapy. Vaginal prophylaxis with oestriol has proven its positive effect without serious gynaecological side effects. Also there is increasing evidence that cranberries prevent rUTI. The exact mode (juice, tablets or preserved berries), dosage and duration of this therapy remain to be defined. There are also promising therapy modalities such as changing bacterial gut flora, general immune response (acupuncture, inpatient rehabilitation) and urine acidity.     

Cystoscopy in women with recurrent urinary tract infection

OBJECTIVE: To investigate if women with recurrent urinary tract infection (UTI) warrant cystoscopy to exclude an abnormality of the lower urinary tract. This is particularly relevant given that non-invasive imaging has often been performed to exclude abnormality. Our further aims were to correlate imaging and risk factors with cystoscopic findings to determine their predictive value in finding pathology. PATIENTS AND METHODS: A database of women undergoing cystoscopy with recurrent UTI has been maintained at our institution for 10 years. We retrospectively examined this and patient records for patient demographics, and investigative and operative data. RESULTS: A total of 118 patients (mean 55 years) having recurrent UTI (mean 4.7 infections/year) were available. There were nine patients (8%) with significant abnormalities at cystoscopy: urethral stricture (six), bladder calculus (one), bladder diverticulum (one) and colovesical fistula (one). The negative predictive value (NPV) of imaging was 99% and significant (P < 0.01). Women with no risk factors for UTI had a NPV of 93% for normal cystoscopy (P > 0.05). The positive predictive value was low for imaging and risk factors in predicting cystoscopy findings. CONCLUSIONS: In our study, 8% of women had significant abnormalities detected during cystoscopy with most over 50 years. Women without risk factors for recurrent UTI and with normal imaging could have a cystoscopy omitted. Younger women are less likely to have pathology and this must be factored into decisions to perform cystoscopy.     

Long-term efficacy of fulguration of trigonitis for recurrent urinary tract infections in women

ObjectiveWomen with a longstanding history of recurrent urinary tract infections (RUTIs) represent a challenging population because of gradual development of antibiotic resistance and frequent antibiotic allergies. We report on the long-term results of women with RUTIs and trigonitis who were treated using endoscopic fulguration and were prospectively followed.Materials and methodsFollowing institutional review board approval, charts of non-neurogenic women with RUTIs (defined as ≥3 UTIs/y), no voiding dysfunction or incontinence, and normal upper tracts by imaging, who underwent cystoscopy with fulguration of trigonitis (CFT) under anesthesia with 1 year minimum follow up after CFT, were reviewed. Trigonitis was defined as a condition of inflammation of the trigone region of the bladder. The primary outcome was complete resolution of trigonitis based on follow-up office cystoscopy 6 months after CFT. The secondary outcome was the total number of antibiotic courses (AC) prescribed for UTI-related symptoms and/or positive urine cultures (PUC) following CFT. We hypothesized that patients with complete trigonitis resolution after CFT fared best.ResultsFrom 2004 to 2008, 33 women met the inclusion criteria with a mean follow up of 48 ± 19 months (range, 14–82 months). Resolution of trigonitis at 6 months was noted in 25 (76%) patients. This group averaged 0.51 ± 0.5 total AC and/or PUC/y compared with 2.03 ± 1.1 total AC and/or PUC/y for women with persistent trigonitis following CFT (p = 0.006).ConclusionPatients with resolved trigonitis at 6 months after CFT did best; however, both groups benefited from the procedure over time.     

Pathogenesis and management of recurrent urinary tract infection in women

A number of pathogenic factors for the development of recurrent urinary tract infection, such as prolonged vaginal colonization with uropathogenic Escherichia coli, nonsecretion of ABH blood-group antigens, impaired local immune response, oestrogen deficiency in postmenopausal women and altered vaginal milieu caused by the use of contraceptives, are involved. Long-term use of antimicrobial agents is the cornerstone of prevention of recurrent urinary tract infection. Other approaches currently used involve self-start (on demand) therapy, oestrogen replacement in postmenopausal women, behavioural changes and alternative therapies, such as acupuncture.     

d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial

Purpose

To test whether d-mannose powder is effective for recurrent urinary tract infection (UTI) prevention.

Materials and methods

After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of d-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis.

Results

Overall 98 patients (31.8 %) had recurrent UTI: 15 (14.6) in the d-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P < 0.001). Patients in d-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P < 0.0001). In active groups, 17.9 % of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in d-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P < 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated.

Conclusions

In our study, d-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that d-mannose may be useful for UTI prevention.     

Effective postcoital prophylaxis of recurrent urinary tract infections in premenopausal women: A review

A total of 77 sexually active premenopausal women, susceptible to recurrent urinary tract infections (UTI) but otherwise healthy, were subjected to postcoital prophylaxis consisting of a single oral dose of either cotrimoxazole (80 mg trimethoprim+400 mg sulfamethoxazole), 50 mg nitrofurantoin macrocrystals, 500 mg nalidixic acid, 250 mg cinoxacin or 250 mg cephalexin. Postcoital prophylaxis reduced the incidence of recurrent UTI from 5-8 UTI per patient/year prior to prophylaxis, to a mere 0.03 UTI per patient/ year following prophylaxis. The differences in the incidence of UTI prior to and following institution of postcoital prophylaxis were statistically highly significant. A mean of 106–120 antibacterial tablets per patient were administered per year.Postcoital prophylaxis of recurrent UTI in premenopausal women is highly effective because of easy compliance, the high urinary concentration achieved and the minimal induction of resistance in the introital Gram-negative bacterial flora, irrespective of the length of time this prophylaxis is used. Furthermore, postcoital prophylaxis is significantly more effective than daily, as it achieves the same effect but requires only one third or fewer of the antibacterial tablets used in daily prophylaxis. At present, postcoital prophylaxis with cotrimoxazole, nitrofurantoin macrocrystals or cephalexin is recommended.     

Effective prophylaxis of recurrent urinary tract infections in premenopausal women by postcoital administration of cephalexin

A total of 31 sexually active premenopausal women, prone to have recurrent urinary tract infections but who otherwise were healthy, underwent postcoital prophylaxis consisting of a single oral dose of 250 mg. cephalexin. While 127 urinary tract infections occurred in these patients during a mean of 6 months before treatment, only 1 occurred during a mean of 12 months after postcoital cephalexin prophylaxis. This difference was statistically highly significant. Each of these patients ingested approximately 120 cephalexin tablets per year of postcoital prophylaxis. Postcoital oral cephalexin prophylaxis is highly effective in the prevention of recurrent urinary tract infection in the nonpregnant as well as pregnant premenopausal women because of easy compliance, the high urine concentration achieved and the minimal induction of resistance to cephalexin in the introital gram-negative bacterial flora. Postcoital cephalexin prophylaxis achieves identical results to daily cephalexin prophylaxis but uses only a third of the tablets required in the daily regimens. Finally, cephalexin represents an additional valuable antibacterial drug in postcoital prophylaxis along with cotrimoxazole, nitrofurantoin and cinoxacin.